Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

Lid margin collarettes are common in moderate-to-severe DED, but most do not progress over time. No link was found between collarettes and dry eye symptoms. DED signs were more severe in eyes with ...

One of the most futuristic components of Hipsley’s work is the Virtual Eye Simulation Analyzer (VESA), an AI-enabled modeling ...

Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...

Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...

AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...